Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Onco Targets Ther ; 9: 1123-33, 2016.
Article in English | MEDLINE | ID: mdl-27042104

ABSTRACT

It has been previously reported that the deregulation of microRNAs in gastric cancer (GC) was correlated with the progression and prognosis. miR-429, a member of the miR-200 family, was previously shown to play an important role in human carcinomas. Our study shows that miR-429 is significantly downregulated in GC tissues compared with matched nontumor tissues. Overexpression of miR-429 in GC cells suppressed cell proliferation. Fascin-1 (FSCN1) was identified as one of the targets of miR-429 and knockdown of FSCN1 mimics the function of miR-429 overexpression. In conclusion, miR-429 acts as a tumor suppressor by targeting FSCN1, suggesting that miR-429 and FSCN1 can both be potential therapeutic targets of GC.

2.
EMBO J ; 35(2): 208-36, 2016 Jan 18.
Article in English | MEDLINE | ID: mdl-26702098

ABSTRACT

Pro-apoptotic Bax induces mitochondrial outer membrane permeabilization (MOMP) by forming oligomers through a largely undefined process. Using site-specific disulfide crosslinking, compartment-specific chemical labeling, and mutational analysis, we found that activated integral membrane Bax proteins form a BH3-in-groove dimer interface on the MOM surface similar to that observed in crystals. However, after the α5 helix was released into the MOM, the remaining interface with α2, α3, and α4 helices was rearranged. Another dimer interface was formed inside the MOM by two intersected or parallel α9 helices. Combinations of these interfaces generated oligomers in the MOM. Oligomerization was initiated by BH3-in-groove dimerization, without which neither the other dimerizations nor MOMP occurred. In contrast, α9 dimerization occurred downstream and was required for release of large but not small proteins from mitochondria. Moreover, the release of large proteins was facilitated by α9 insertion into the MOM and localization to the pore rim. Therefore, the BH3-in-groove dimerization on the MOM nucleates the assembly of an oligomeric Bax pore that is enlarged by α9 dimerization at the rim.


Subject(s)
Mitochondrial Membranes/metabolism , bcl-2-Associated X Protein/metabolism , Animals , Apoptosis/genetics , Apoptosis/physiology , Cell Line , Dimerization , Immunoprecipitation , Protein Binding , bcl-2 Homologous Antagonist-Killer Protein/genetics , bcl-2 Homologous Antagonist-Killer Protein/metabolism , bcl-2-Associated X Protein/genetics
3.
Mol Biol Cell ; 27(1): 127-36, 2016 Jan 01.
Article in English | MEDLINE | ID: mdl-26538028

ABSTRACT

Coat protein complexes contain an inner shell that sorts cargo and an outer shell that helps deform the membrane to give the vesicle its shape. There are three major types of coated vesicles in the cell: COPII, COPI, and clathrin. The COPII coat complex facilitates vesicle budding from the endoplasmic reticulum (ER), while the COPI coat complex performs an analogous function in the Golgi. Clathrin-coated vesicles mediate traffic from the cell surface and between the trans-Golgi and endosome. While the assembly and structure of these coat complexes has been extensively studied, the disassembly of COPII and COPI coats from membranes is less well understood. We describe a proteomic and genetic approach that connects the J-domain chaperone auxilin, which uncoats clathrin-coated vesicles, to COPII and COPI coat complexes. Consistent with a functional role for auxilin in the early secretory pathway, auxilin binds to COPII and COPI coat subunits. Furthermore, ER-Golgi and intra-Golgi traffic is delayed at 15°C in swa2Δ mutant cells, which lack auxilin. In the case of COPII vesicles, we link this delay to a defect in vesicle fusion. We propose that auxilin acts as a chaperone and/or uncoating factor for transport vesicles that act in the early secretory pathway.


Subject(s)
Auxilins/genetics , Auxilins/metabolism , Clathrin-Coated Vesicles/metabolism , COP-Coated Vesicles/genetics , COP-Coated Vesicles/metabolism , Clathrin/metabolism , Clathrin-Coated Vesicles/genetics , Endoplasmic Reticulum/metabolism , Golgi Apparatus/metabolism , Membrane Proteins/metabolism , Protein Transport/physiology , Proteomics , Saccharomyces cerevisiae/metabolism , Saccharomyces cerevisiae Proteins/metabolism , Secretory Pathway/physiology , Vesicular Transport Proteins/metabolism
4.
J Cell Biol ; 210(2): 273-85, 2015 Jul 20.
Article in English | MEDLINE | ID: mdl-26195667

ABSTRACT

ER-derived COPII-coated vesicles are conventionally targeted to the Golgi. However, during cell stress these vesicles also become a membrane source for autophagosomes, distinct organelles that target cellular components for degradation. How the itinerary of COPII vesicles is coordinated on these pathways remains unknown. Phosphorylation of the COPII coat by casein kinase 1 (CK1), Hrr25, contributes to the directional delivery of ER-derived vesicles to the Golgi. CK1 family members are thought to be constitutively active kinases that are regulated through their subcellular localization. Instead, we show here that the Rab GTPase Ypt1/Rab1 binds and activates Hrr25/CK1δ to spatially regulate its kinase activity. Consistent with a role for COPII vesicles and Hrr25 in membrane traffic and autophagosome biogenesis, hrr25 mutants were defective in ER-Golgi traffic and macroautophagy. These studies are likely to serve as a paradigm for how CK1 kinases act in membrane traffic.


Subject(s)
Casein Kinase I/metabolism , Endoplasmic Reticulum/enzymology , Golgi Apparatus/enzymology , Saccharomyces cerevisiae Proteins/metabolism , Saccharomyces cerevisiae Proteins/physiology , Saccharomyces cerevisiae/enzymology , rab GTP-Binding Proteins/physiology , Autophagy , COP-Coated Vesicles/metabolism , Humans , Protein Transport
5.
Oncol Rep ; 33(2): 856-60, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25500894

ABSTRACT

Patrinia scabiosaefolia (PS) has long been used as an important component in traditional Chinese medicine formulas to treat gastrointestinal malignancies including colorectal cancer (CRC). We recently reported that PS can inhibit CRC growth through induction of apoptosis and inhibition of tumor angiogenesis. To further elucidate the mode of action of PS, in the present study, we used a CRC mouse xenograft model and a human CRC cell line HT-29 to evaluate the effect of the ethanol extract of PS (EEPS) on cancer cell proliferation and investigated the underlying molecular mechanisms. We found that EEPS inhibited CRC growth both in vivo and in vitro, which was associated with the inhibitory effects of EEPS on cancer cell proliferation. In addition, EEPS treatment significantly blocked G1 to S phase cell cycle progression in HT-29 cells. Moreover, EEPS treatment decreased the expression of pro-proliferative CyclinD1 and CDK4, at both the mRNA and protein levels. Thus, inhibition of cell proliferation via G1/S cell cycle arrest might be a potential mechanism whereby PS effectively treats cancers.


Subject(s)
Colorectal Neoplasms/drug therapy , Colorectal Neoplasms/metabolism , Patrinia/chemistry , Plant Extracts/chemistry , Animals , Apoptosis , Cell Cycle , Cell Line, Tumor , Cell Proliferation , Cell Survival , Cyclin D1/metabolism , Cyclin-Dependent Kinase 4/metabolism , Disease Progression , Ethanol/chemistry , G1 Phase Cell Cycle Checkpoints , Humans , Male , Mice , Mice, Inbred BALB C , Neoplasm Transplantation , Neovascularization, Pathologic , RNA, Messenger/metabolism , S Phase
6.
J Biol Chem ; 289(17): 11873-11896, 2014 Apr 25.
Article in English | MEDLINE | ID: mdl-24616095

ABSTRACT

Bcl-XL binds to Bax, inhibiting Bax oligomerization required for mitochondrial outer membrane permeabilization (MOMP) during apoptosis. How Bcl-XL binds to Bax in the membrane is not known. Here, we investigated the structural organization of Bcl-XL·Bax complexes formed in the MOM, including the binding interface and membrane topology, using site-specific cross-linking, compartment-specific labeling, and computational modeling. We found that one heterodimer interface is formed by a specific interaction between the Bcl-2 homology 1-3 (BH1-3) groove of Bcl-XL and the BH3 helix of Bax, as defined previously by the crystal structure of a truncated Bcl-XL protein and a Bax BH3 peptide (Protein Data Bank entry 3PL7). We also discovered a novel interface in the heterodimer formed by equivalent interactions between the helix 1 regions of Bcl-XL and Bax when their helical axes are oriented either in parallel or antiparallel. The two interfaces are located on the cytosolic side of the MOM, whereas helix 9 of Bcl-XL is embedded in the membrane together with helices 5, 6, and 9 of Bax. Formation of the helix 1·helix 1 interface partially depends on the formation of the groove·BH3 interface because point mutations in the latter interface and the addition of ABT-737, a groove-binding BH3 mimetic, blocked the formation of both interfaces. The mutations and ABT-737 also prevented Bcl-XL from inhibiting Bax oligomerization and subsequent MOMP, suggesting that the structural organization in which interactions at both interfaces contribute to the overall stability and functionality of the complex represents antiapoptotic Bcl-XL·Bax complexes in the MOM.


Subject(s)
Apoptosis , Mitochondria/metabolism , Proto-Oncogene Proteins c-bcl-2/metabolism , bcl-2-Associated X Protein/metabolism , bcl-X Protein/metabolism , Amino Acid Sequence , Binding Sites , Dimerization , Models, Molecular , Molecular Sequence Data , Permeability , Proto-Oncogene Proteins c-bcl-2/chemistry , bcl-2-Associated X Protein/chemistry , bcl-X Protein/chemistry
7.
Stem Cell Investig ; 1: 22, 2014.
Article in English | MEDLINE | ID: mdl-27358868

ABSTRACT

Oncolytic viruses (OVs), which were discovered more than one century ago, have been used in multiple clinical trials for cancer therapy. OVs specifically target cancer cells when sparing normal cells by exploiting biochemical differences between normal and tumor cells. Hence oncolytic virotherapy is more specific at targeting cancer cells compared with conventional anti-cancer therapy. Apart from the lack of specificity, conventional anti-cancer therapies also often witness relapse and incomplete cure of cancer. One hypothesis explaining this phenomenon is that a subpopulation of cancer cells, known as cancer stem cells (CSCs), are resistant to conventional therapies, possibly due to its self-renewal and differentiation abilities. With the discovery of CSCs, researchers have been trying to explain whether OVs are well suited to eliminate CSCs. Two explanations for postulating OVs as ideal candidates for cancer therapy have been proposed: first, OVs are not subject to the same mechanisms responsible for chemotherapy and radiation resistance; second, viruses could be harnessed to express therapeutic transgenes that specifically target the features unique to CSCs or the properties CSCs rely on for self-renewal and differentiation. Indeed, initial studies suggest that OVs could effectively target CSCs in multiple tumor types. The focus of this review is to highlight recent studies related to the application of OVs on targeting CSCs, based on which, the challenges and perspectives for further research in this field will also be discussed.

8.
J Biol Chem ; 285(37): 28749-63, 2010 Sep 10.
Article in English | MEDLINE | ID: mdl-20584903

ABSTRACT

The interaction of Bcl-2 family proteins at the mitochondrial outer membrane controls membrane permeability and thereby the apoptotic program. The anti-apoptotic protein Bcl-2 binds to the pro-apoptotic protein Bax to prevent Bax homo-oligomerization required for membrane permeabilization. Here, we used site-specific photocross-linking to map the surfaces of Bax and Bcl-2 that interact in the hetero-complex formed in a Triton X-100 micelle as a membrane surrogate. Heterodimer-specific photoadducts were detected from multiple sites in Bax and Bcl-2. Many of the interaction sites are located in the Bcl-2 homology 3 (BH3) region of Bax and the BH1-3 groove of Bcl-2 that likely form the BH3-BH1-3 groove interface. However, other interaction sites form a second interface that includes helix 6 of Bax and the BH4 region of Bcl-2. Loss-of-function mutations in the BH3 region of Bax and the BH1 region of Bcl-2 disrupted the BH3-BH1-3 interface, as expected. Surprisingly the second interface was also disrupted by these mutations. Similarly, a loss-of-function mutation in the BH4 region of Bcl-2 that forms part of the second interface also disrupted both interfaces. As expected, both kinds of mutation abolished Bcl-2-mediated inhibition of Bax oligomerization in detergent micelles. Therefore, Bcl-2 binds Bax through two interdependent interfaces to inhibit the pro-apoptotic oligomerization of Bax.


Subject(s)
Mutation , Protein Multimerization/physiology , Proto-Oncogene Proteins c-bcl-2/chemistry , bcl-2-Associated X Protein/chemistry , Amino Acid Motifs , Animals , Humans , Protein Binding , Protein Structure, Quaternary , Proto-Oncogene Proteins c-bcl-2/genetics , Proto-Oncogene Proteins c-bcl-2/metabolism , Rats , bcl-2-Associated X Protein/genetics , bcl-2-Associated X Protein/metabolism
9.
J Biol Chem ; 285(23): 17614-27, 2010 Jun 04.
Article in English | MEDLINE | ID: mdl-20382739

ABSTRACT

Interactions of Bcl-2 family proteins regulate permeability of the mitochondrial outer membrane and apoptosis. In particular, Bax forms an oligomer that permeabilizes the membrane. To map the interface of the Bax oligomer we used Triton X-100 as a membrane surrogate and performed site-specific photocross-linking. Bax-specific adducts were formed through photo-reactive probes at multiple sites that can be grouped into two surfaces. The first surface overlaps with the BH1-3 groove formed by Bcl-2 Homology motif 1, 2, and 3; the second surface is a rear pocket located on the opposite side of the protein from the BH1-3 groove. Further cross-linking experiments using Bax BH3 peptides and mutants demonstrated that the two surfaces interact with their counterparts in neighboring proteins to form two separated interfaces and that interaction at the BH1-3 groove primes the rear pocket for further interaction. Therefore, Bax oligomerization proceeds through a series of interactions that occur at separate, yet allosterically, coupled interfaces.


Subject(s)
Apoptosis , bcl-2-Associated X Protein/metabolism , Allosteric Site , Amino Acid Motifs , Biochemistry/methods , Cross-Linking Reagents/chemistry , Detergents/pharmacology , Humans , Mutation , Octoxynol/pharmacology , Peptides/chemistry , Plasmids/metabolism , Protein Binding , Protein Structure, Tertiary , Proto-Oncogene Proteins c-bcl-2/chemistry
10.
Apoptosis ; 14(10): 1145-53, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19701793

ABSTRACT

Both pro-apoptotic Bax and anti-apoptotic Bcl-2 are structurally homologous to the pore-forming domain of bacterial toxins. Bax proteins oligomerize in the mitochondrial outer membranes forming pores that release cytochrome c from the mitochondrial intermembrane space. Bcl-2 proteins also form pores that, however, are much smaller than the Bax pore. It is unknown whether Bcl-2 forms monomeric or oligomeric pores. Here, we characterized the Bcl-2 pore formation in liposomes using biophysical and biochemical techniques. The results show that the Bcl-2 pore enlarges as the concentration of Bcl-2 increases, suggesting that the pore is formed by Bcl-2 oligomers. As expected from oligomerization-mediated pore-formation, the small pores are formed earlier than the large ones. Bcl-2 oligomers form pores faster than the monomer, indicating that the oligomerization constitutes an intermediate step of the pore formation. A Bcl-2 mutant with higher affinity for oligomerization forms pores faster than wild type Bcl-2. Bcl-2 oligomers were detected in the liposomal membranes under conditions that Bcl-2 forms pores, and the extent of oligomerization was positively correlated with the pore-forming activity. Therefore, Bcl-2 oligomerizes in membranes forming pores, but the extent of oligomerization and the size of the resulting pores are much smaller than that of Bax, supporting the model that Bcl-2 is a defective Bax.


Subject(s)
BH3 Interacting Domain Death Agonist Protein/metabolism , Cell Membrane/metabolism , Porins/metabolism , Protein Multimerization , Proto-Oncogene Proteins c-bcl-2/metabolism , Cell Membrane/drug effects , Chromatography, Gel , Cross-Linking Reagents/pharmacology , Kinetics , Liposomes/metabolism , Models, Biological , Molecular Weight , Mutation/genetics , Protein Binding/drug effects , Protein Multimerization/drug effects , bcl-2-Associated X Protein/metabolism
11.
Hereditas ; 143(2006): 236-45, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17362360

ABSTRACT

Plant height and tiller number are two important characters related to yield in rice (Oriza sativa L.). Zhenshan97 x Minghui63 recombinant inbred lines were employed to dissect the genetic basis of development of plant height and tiller number using conditional and unconditional composite interval mapping approaches. The traits were normally distributed with transgressive segregation in both directions. Increasingly negative correlations were observed between tiller number and plant height at five consecutive growth stages. A total of 23 and 24 QTL were identified for tiller number and plant height, respectively. More QTL were detected by conditional mapping than by conventional mapping. Different QTL/genes apparently controlled the traits at different developmental stages. Three genomic regions were identified as putative co-located QTL, which showed opposite additive effects on tiller number and plant height. Furthermore, in the period reaching maximum tiller number, the expression of QTL for tiller number was active, whereas that of QTL for plant height was inactive. These facts provided a possible genetic explanation for the negative correlations between the traits. The research demonstrates conditional mapping to be superior to conventional mapping for this type of research. Implications of the results for hybrid rice improvement are discussed.


Subject(s)
Oryza/genetics , Breeding , Chromosome Mapping , Oryza/growth & development , Phenotype , Quantitative Trait Loci
SELECTION OF CITATIONS
SEARCH DETAIL
...